Cycle Pharmaceuticals (Cycle) has launched Cycle Vita PKU, an AI-powered app to help patients with PKU manage every aspect of their treatment plan. It can be challenging for patients with PKU ...

"This positive opinion is great news for the PKU patient community in Europe for whom there remains a significant unmet medical need," said Matthew B. Klein, M.D., Chief Executive Officer of PTC ...

Pegvaliase, a phenylalanine (Phe)-metabolizing enzyme, is currently marketed under the brand name Palynziq ® to reduce blood Phe concentrations in adult patients with PKU who have uncontrolled ...

Sephience is designed to reduce blood phenylalanine (Phe) levels in PKU patients, a rare metabolic disease that can lead to severe and irreversible disabilities if untreated. The drug’s dual mechanism ...

Such positive data was achieved in this late-stage study targeting adolescent patients ages 12 - 17 with PKU specifically. The reason this drug has already been approved to treat adults with this ...

MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026MZE782 Phase 1 Healthy Volunteer ...

Cycle Pharmaceuticals (Cycle) has launched Cycle Vita PKU, an AI-powered app to help patients with PKU manage every aspect of ...